Evidence map›Paper›PMID 40346938›Full record

ReviewJournal of sleep research2025

Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy.

Brooke A Prakash, Ishani Shah, Guohao Ni, Sridhar Vasudevan, Aarti Jagannath, Russell G Foster

Abstract readHistorical ArticleReview
In one paragraph

Review in Journal of sleep research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Insomnia disorder.Nature reviews. Disease primers · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brooke A PrakashDepartment of Pharmacology, University of Oxford, Oxford, UK.ORCID 0009-0008-9858-3625
Ishani ShahDepartment of Pharmacology, University of Oxford, Oxford, UK.
Guohao NiDepartment of Pharmacology, University of Oxford, Oxford, UK.
Sridhar VasudevanDepartment of Pharmacology, University of Oxford, Oxford, UK.
Aarti JagannathNuffield Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute (SCNi), University of Oxford, Oxford, UK.ORCID 0000-0003-2132-8200
Russell G FosterNuffield Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute (SCNi), University of Oxford, Oxford, UK.

Funding

Biotechnology and Biological Sciences Research Council BB/W016486/1Biotechnology and Biological Sciences Research Council BB/Y005848/1BMS-Celgene
6 · The paper itself

Abstract

Throughout history, the development of new sleep medicines has been driven by progress in our understanding of the mechanisms underlying sleep. Ancient civilisations used their understanding of the sedative nature of natural herbs and compounds to induce sleep. The discovery of barbiturates and bromides heralded a new era of synthetic sleep medicine in the 19th century. This was followed by the development of benzodiazepines that were used to inhibit signalling throughout the brain by promoting gamma-amino butyric acid release and thereby produce loss of consciousness. As our understanding of sleep has deepened, newer therapies have more specifically targeted the wake-inducing neurotransmitter orexin with fewer side effects. Given the newly highlighted role of kinases in sleep/wake regulation, we predict that the next breakthroughs in sleep medicine will likely target these kinases. Given the fundamental role that sleep plays in maintaining brain health through processes such as glymphatic clearance, sleep medicine has therapeutic potential beyond just sleep. Recent evidence suggests that sleep disruptions directly contribute to the build-up of pathological neuronal proteins in neurodegenerative disorders. Therefore, sleep medicine could improve prognosis in disorders such as these. Great attention must be paid to the mechanism of action of each sleep medicine, however, as sleep medicines which do not fully mimic sleep could actually worsen disease progression.

Indexed as

ChronotherapySleepSleep Medicine SpecialtySleep Wake DisordersAnimalsDrug DevelopmentHistory, 20th CenturyHumansMelatoninMolecular Targeted TherapyNeurodegenerative DiseasesOrexin Receptor AntagonistsMelatoninOrexin Receptor AntagonistschronotherapycircadianGABAglymphatic clearancekinasesmelatoninneurodegenerationorexinsleepsleep medicine

Identifiers

PMID40346938
PMCPMC12426713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.